Cara Therapeutics (CARA) Misses Q4 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. COF
6. SMCI
7. RTX
8. TSLA
9. CRWV
10. S

Go back to Cara Therapeutics (CARA) Misses Q4 EPS by 3c

Cara Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

March 15, 2018 4:01 PM EDT

STAMFORD, Conn., March 15, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors, today announced financial results for the fourth quarter and full year ended December 31, 2017.

We are very pleased with the progress we have made with both I.V. and oral KORSUVA across our ongoing clinical programs in pruritus and with CR845/difelikefalin in pain, including the recent initiation of our first pivotal Phase 3 trial of I.V. KORSUVA in... More